Cytoskeleton alteration in MCF7R cells, a multidrug resistant human breast cancer cell line

Anticancer Research

Volumn 17, Issue 5 A, 1997, Pages 3393-3401

  Bichat, Francis ^a   Mouawad, Roger ^a   Solis Recendez, Guadalupe ^a   Khayat, David ^a   Bastian, Gerard ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Breast cancer MCF7; Cytoskeleton; Intermediate filaments; Multidrug resistance; Reversal activities

Indexed keywords

CYTOKERATIN; DOXORUBICIN; VIMENTIN;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; CULTURE MEDIUM; CYTOSKELETON; ELECTROPHORESIS; EPITHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; INTERMEDIATE FILAMENT; MALIGNANT TRANSFORMATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CYTOSKELETON; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; HUMANS; KERATINS; P-GLYCOPROTEIN; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED; VIMENTIN;

EID: 0030731233     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Paine ML, Gibbins JR, Choi JKW, MacDonald DA, Manthey AM, Walker DM, Kefford RF: Intranuclear post-transcriptional down-regulation responsible for loss of a keratin differentiation marker in tumour progression. Anticancer Res 15: 2145-2154, 1995.
2. Modjtahedi N, Frebourg T, Fossar N, Lavialle C, Cremisi C, Brison O: Increased expression of cytokeratin and ferritin-H genes in tumorigenic clones of the SW 613-S human colon carcinoma cell line. Exp Cell Res 201: 74-82, 1992.
3. Wauters CCAP, Smedts FL, Gerrits GM, Bosman FT, Ramaekers FCS: Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum Path 26: 852-855, 1995.
4. Steinert PM, Liem RK: Intermediate filament dynamics. Cell 60: 521-523, 1990.
5. Steinert PM, Roop DR: Molecular and cellular biology of intermediate filaments. Annu Rev Biochem 57: 593-625, 1988.
6. Hartzfeld M, Franke WW: Pair formation and promiscuity of cytokeratins: formation in vitro of heterotypic complexes and intermediate-sized filaments by homologous and heterologous recombinations of purified polypeptides. J Cell Biol 101: 1826-1841, 1985.
7. Quinlan RA, Cohlberg JA, Schiller DL, Hartzfeld M, Franke WW: Heterotypic tetramer (A2D2) complexes of non-epidermal keratins isolated from cytoskeletons of rat hepatocytes and hepatoma cells. J Mol Biol 178: 365-388, 1984.
8. Van Dalen A: Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 211 in metastatic disease. Anticancer Res 76; 2345-2350, 1996.
9. Quinlan RA, Franke WW: Heteropolymer filaments of vimentin and desmin in vascular smooth muscle tissue and cultured baby hamster kidney cells demonstrated chemical crosslinking. Proc Natl Acad Sci USA 79: 3452-3456, 1982.
10. Chou YH, Rosevear E, Goldman R: Phosphorylation and disassembly of intermediate filaments in mitotic cells. Proc Natl Acad Sci USA 86: 1885-1889, 1989.
11. Gurland G, Gundersen GG: Stable, detyrosinated microtubules function to localize vimentin intermediate filaments in fibroblasts. J Cell Biol 131: 1275-1290, 1995.
12. Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima T, Torri JA, Donnahue M, Lippman ME, Martin GR, Dickson RB: Association of increased basement membrane-invasiveness with absence of estrogen receptor and expression of vimentin in human malignant breast epithelium. J Cell Physiol 150: 534-544, 1992.
13. Chu YW, Seftor EA, Romer LH, Hendrix MJC: Experimental coexpression of vimentin and keratin intermediate filaments in human melanoma cells augments motility. Am J Path 148: 63-69, 1996.
14. Hendrix MJC, Seftor,EA, Chu YW, Seftor REB, Nagle RB, McDaniel KM, Leong SPL, Yohem KH, Leibovitz AM, Meyskens FL, Conaway DH, Welch DR, Liotta LA, Stetler-Stevenson W: Coexpression of vimentin and keratins by human melanoma tumor cells : correlation with invasive and metastatic potential. J Natl Cancer Inst 84: 165-174, 1992.
15. Tsuru A, Nakamura N, Takayama E, Suzuki Y, Hirayoshi K, Nagata K: Regulation of the expression of vimentin gene during the differentiation of mouse myeloid leukemia cells. J Cell Biol 110: 1655-1664, 1990.
16. Seshadri R, Raymond WA, Leong ASY, Horsfall DJ, McCaul K: Vimentin expression is not associated with poor prognosis in breast cancer. Int J Cancer 67: 353-356, 1996.
17. Cattoretti G, Andreola S, Clemente C, D'Amato L, Rilke F: Vimentin and p53 expression on epidermal growth factor receptor-positive, estrogen receptor-negative breast carcinomas. Br J Cancer 57: 353-357, 1988.
18. Moll R, Franke WW, Schiller DL: The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31: 11-24, 1982.
19. Pieper FR, Van De Klundert FA, Raats JM, Henderik JB, Schaart G, Ramaekers FC, Bloemendal H: Regulation of vimentin expression in cultured epithelial cells. Eur J Biochem 270: 509-519, 1992.
20. Conforti G, Codegoni AM, Scanziani E, Dolfini E, Dastia T, Calza M, Caniatti M, Broggini M: Different vimentin expression in two clones derived from a human colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin. Br J Cancer 71: 505-511, 1995.
21. Sommers CL, Heckford SE, Skerker JM, Worland P, Torri JA, Thompson EW, Byers SW, Gelmann EP: Loss of epithelial markers and acquisition of vimentin expression in adriamycin and vinblastine-resistant human breast cancer cell lines. Cancer Res 52: 5190-5197, 1992.
22. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
23. Gottlieb M, Chavko M: Silver staining of native and denatured eucaryotic DNA in agarose gels. Anal Biochem 165: 33-37, 1987.
24. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4354, 1979.
25. Endicott JA, Ling V: The biochemistry of p-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137-171, 1989.
26. Ford JM, Hait WM: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-199, 1990.
27. Goldman RP, Goldman AE, Gree KJ: Intermediate filaments networks: Organization and possible functions of a diverse group of cytoskeletal elements. J Cell Sci 5: 69-97, 1986.
28. Paine ML, Gibbins JR, Chew KE, Demetriou A, Kefford RF: Loss of keratin expression in anaplastic carcinoma cells due to post-transcriptional down-regulation acting in trans. Cancer Res 52: 6603-6611, 1992.
29. Sommers CL, Byers SW, Thompson EW, Torn JA, Gelmann EP: Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res and Treat 31: 325-335, 1994.
30. Paulin-Levasseur M, Julien M: Expression of intermediate filament proteins in TPA-induced MPC-11 and HL-60 cells. Exp Cell Res. 199: 363-372, 1992.
31. Chan R, Rossito PV, Edwards BF, Cardiff BF: Presence of proteolytically processed keratins in culture medium of MCF7 cells. Cancer Res 46: 6363-6359, 1986.
32. ++-activated protease specific for the intermadiate-sized filament protein vimentin in Ehrlich ascites-tumour cells. Eur J Biochem 116: 51-57, 1981.
33. Ducan TH, Roberge M: The antitumor drug fostriecin induces vimentin hyperphosphorylation and intermediate filament reorganisation. Carcinogenesis 17: 967-972, 1996.
34. Palladini G, Finardi G, Bellomo G: Modifications of vimentin filament architecture and vimentin-nuclear interactions by cholesterol oxides in 73/73 endothelial cells. Exp Cell Res 223: 83-90, 1996.